Repligen Corp Net Income per Employee (RGEN), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Repligen Corp  (NASDAQ: RGEN)
 

Repligen Net Income per Employee

RGEN's Quarterly Results, Trends, Rankings, Statistics
Repligen Corp recorded a cumulative net loss of $-12 million during 12 month ending in the third quarter 2026.
The Healthcare sector has seen employees of 20 other companies achieving higher income per employee. While Repligen's total ranking has deteriorated compared to the previous quarter from 1150 to 1714.


What is Income per Employee Ratio?





Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RGEN Net Income per Employee (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Net Income Change - -66.31 % 42.93 % - -
Net Income per Employee (TTM) $ -5,902 20,770 25,699 24,447 869
RGEN's Total Ranking # 1714 # 1150 # 1609 # 2157 #
Seq. Net Income Change - -39.9 % -37.28 % -10.89 % 0.3 %

RGEN Company Profile >> Back to RGEN Efficiency Comparisons >> Compare RGEN Net Income per Employee to its Competitors

RGEN Net Income per Employee Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 21
Healthcare Sector # 146
Overall Market # 1714

Net Income per Employee Statistics
High Average Low
$ 92,980 $ 19,644 $ -12,757
(Dec 31 2022)   (Dec 31 2024)




  News about Repligen Corp Income per employee

Repligen's Private Convertible Transaction Marks a $600 Million Milestone, Strengthening Financial Position and Driving Growth

Repligen Corporation, a leading biotechnology and pharmaceutical company, has recently made a significant announcement regarding a private convertible transaction. On December 6, 2023, Repligen entered into privately negotiated exchange and subscription agreements with specific holders of its outstanding 0.375% Convertible Senior Notes due 2024 (the 2024 Notes) as well as new investors. This transaction will allow Repligen to issue $600 million worth of 1.00% Convertible Senior Notes due 2028 (the New Notes).
Under these agreements, approximately $309.9 million principal amount of the New Notes will be exchanged for around $217.7 million principal amount of the 2024 Notes. Moreover, approximately $290.1 million principal amount of the New Notes will be issued for cash. Collectively, these transactions, known as the Exchange Transactions and Subscription Transactions, reveal Repligen s strategic effort to optimize its financial position.




Companies with similar Income per Employee for 12 month ending Sep 30 2026, within Healthcare Sector Income per Employee Income 12 month ending Sep 30 2026Number of Employees Sep 30 2026


Date modified: 2026-10-31T17:28:06+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.